Advertisement

Topics

Magenta Therapeutics, Inc. Company Profile

17:49 EST 11th December 2018 | BioPortfolio


News Articles [734 Associated News Articles listed on BioPortfolio]

Jason Ryan of Foundation Medicine Joins Magenta’s C-Suite

Magenta Therapeutics (NASDAQ: MGTA) has appointed Jason Ryan to serve as chief operating and financial officer, effective Jan. 1. Ryan is joining Cambridge, MA-based Magenta from Foundation Medicine, ...

Initial public offering nets $93mm for Magenta Therapeutics

Magenta Therapeutics Inc. (curative stem cell transplantation) netted $93mm through its initial public offering of 6.67mm common shares at $15, the midpoint of its anticipated range.

A Closer Look: Magenta Therapeutics IPO

Magenta Therapeutics to Host Webcast of Investor and Analyst Event During ASH

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patient...

Magenta Therapeutics: This June IPO Should Be On Your Radar

Magenta Therapeutics Readies $100 IPO Plans

Heidelberg Pharma inks US$334m R&D contract with Magenta Therapeutics

Magenta Therapeutics to Present at Wedbush PacGrow Healthcare Conference

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patient...

PubMed Articles [460 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Automated sequential chromogenic IHC double staining with two HRP substrates.

Automated IHC double staining using diaminobenzidine and HRP Magenta is illustrated utilizing a new acidic block with sulfuric acid to prevent cross-reactivity. Residual cross-reactivity in double sta...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Clinical Trials [166 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1284 Associated Companies listed on BioPortfolio]

Magenta Therapeutics Inc.

Magenta Therapeutics is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic di...

Magenta Therapeutics

Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based dise...

Magenta Therapeutics, Inc.

Magenta Medical Inc.

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

More Information about "Magenta Therapeutics, Inc." on BioPortfolio

We have published hundreds of Magenta Therapeutics, Inc. news stories on BioPortfolio along with dozens of Magenta Therapeutics, Inc. Clinical Trials and PubMed Articles about Magenta Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Magenta Therapeutics, Inc. Companies in our database. You can also find out about relevant Magenta Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record